Previous systematic reviews and meta-analyses have reported impressive antidepressant effects of ketamine in treatment-resistant depression (TRD). While ketamine has been compared with electroconvulsive therapy (ECT), the gold standard treatment, the extent and durability of its antidepressant effects over longer periods remain unclear. To our knowledge, this is the first systematic review comparing average time-to-relapse between ECT and ketamine in TRD.
Aims:
To compare the average time-to-relapse between ECT and ketamine for TRD.
Method:
We conducted this systematic review using PubMed, Medline, ScienceDirect, Cochrane Library, Ovid, PsycNET, Embase and Google Scholar, against predetermined criteria. PROSPERO ID: CRD42025643824.
Results:
Thirteen studies met inclusion criteria: 10 examined ketamine/(s)ketamine, and 3 focused on ECT. Twelve were randomised controlled trials (RCTs), and one was retrospective. Heterogeneity was observed in dosing regimens and administration schedules, with some studies having limited follow-up and small sample sizes. Findings are synthesised narratively. In summary, there is evidence for sustained therapeutic potential of both ECT and ketamine, ECT possibly being associated with longer remission. Increased dose, frequency and use of maintenance ECT/ketamine appear to prolong remission, and continuing oral antidepressants may prolong this further. It should also be noted that this review excluded studies involving psychotic depression, leading to the exclusion of some head-to-head studies, thus limiting the generalisability of the findings in these populations.
Conclusion:
There is currently a lack of studies within our inclusion criteria that directly compare time-to-relapse after ECT and ketamine, preventing formal statistical analysis. More high-quality, large-scale RCTs directly comparing these treatment modalities with longer follow-up times are needed.
Aan het RotMCollinsKAMurroughJW, et al. (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry67(2): 139–145.
2.
AlbottCSLimKOForbesMK, et al. (2018) Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. The Journal of Clinical Psychiatry79(3): 17m11634.
3.
Al-Harbi (2012) Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Preference and Adherence6: 369–388.
4.
Arias de la TorreJVilagutGRonaldsonA, et al. (2021) Prevalence and age patterns of depression in the United Kingdom. A population-based study. Journal of Affective Disorders279: 164–172.
5.
BahjiAVazquezGHZarateCA (2021) Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Journal of Affective Disorders278: 542–555.
6.
DalyEJSinghJBFedgchinM, et al. (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiatry75(2): 139.
7.
EkstrandJFattahCPerssonM, et al. (2022) Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: A randomized, open-label, non-inferiority trial (KetECT). International Journal of Neuropsychopharmacology25(5): 339–349.
8.
ElenaMACardonerNGálvezV, et al. (2021) Can the addition of maintenance electroconvulsive therapy to pharmacotherapy improve relapse prevention in severe major depressive disorder? A randomized controlled trial. Brain Sciences11(10): 1340.
9.
FountoulakisKNSaitisASchatzbergAF (2025) Esketamine treatment for depression in adults: A PRISMA systematic review and meta-analysis. American Journal of Psychiatry182(3): 259–275.
10.
GagnéGGFurmanMJCarpenterLL, et al. (2000) Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. American Journal of Psychiatry157(12): 1960–1965.
11.
GluePLooCFamJ, et al. (2024) Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nature Medicine30(7): 2004–2009. https://doi.org/10.1038/s41591-024-03063-x
12.
GuoJQiuDGuH, et al. (2023) Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies. Molecular Psychiatry28(6): 2266–2276. https://doi.org/10.1038/s41380-023-01945-z
13.
HardeveldFSpijkerJDe GraafR, et al. (2010) Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatrica Scandinavica122(3): 184–191.
14.
HigginsJPTThomasJChandlerJ, et al. (2024) Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Available at: https://www.training.cochrane.org/handbook (accessed 26 March 2025).
15.
IbrahimLDiazGranadosNFranco-ChavesJ, et al. (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology37(6): 1526–1533.
16.
JelovacAKolshusEMcLoughlinDM (2013) Relapse following successful electroconvulsive therapy for major depression: A meta-analysis. Neuropsychopharmacology38(12): 2467–2474.
17.
JoneborgILeeYDi VincenzoJD, et al. (2022) Active mechanisms of ketamine-assisted psychotherapy: A systematic review. Journal of Affective Disorders315: 105–112.
18.
KellnerCHKnappRGPetridesG, et al. (2006) Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression. Archives of General Psychiatry63(12): 1337–1344.
19.
KellnerCHHusainMMKnappRG, et al. (2016) A novel strategy for continuation ECT in geriatric depression: Phase 2 of the PRIDE study. American Journal of Psychiatry173(11): 1110–1118.
20.
KhanAReddingNBrownWA (2008) The persistence of the placebo response in antidepressant clinical trials. Journal of Psychiatric Research42(10): 791–796.
21.
KirschI (2019) Placebo effect in the treatment of depression and anxiety. Frontiers in Psychiatry10: 407.
22.
KurimotoNInagakiTAokiT, et al. (2021) Factors causing a relapse of major depressive disorders following successful electroconvulsive therapy: A retrospective cohort study. World Journal of Psychiatry11(10): 841–853.
23.
MathewSJMurroughJWaan het RotM, et al. (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. International Journal of Neuropsychopharmacology13(1): 71–82.
24.
Martínez-AmorósECardoner N, GálvezV, et al. (2021) Can the addition of maintenance electroconvulsive therapy to pharmacotherapy improve relapse prevention in severe major depressive disorder? A randomized controlled trial. Brain Sciences11(10): 1340. https://doi.org/10.3390/brainsci11101340
25.
McGuinnessLAHigginsJPT (2020) robvis: An R package and web application for visualising risk-of-bias assessments. Research Synthesis Methods12(1): 55–61.
26.
MethleyAMCampbellSChew-GrahamC, et al. (2014) PICO, PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Services Research14(1): 579.
27.
MoksnesK (2011) Tilbakefall etter elektrokonvulsiv terapi. Tidsskrift for Den norske legeforening131(20): 1991–1993.
28.
MurroughJWPerezAMPillemerS, et al. (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry74(4): 250–256.
29.
PageMJMcKenzieJEBossuytPM, et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Medicine18(3): e1003583.
30.
PloskiJEVaidyaVA (2021) The neurocircuitry of posttraumatic stress disorder and major depression: Insights into overlapping and distinct circuit dysfunction—A tribute to Ron Duman. Biological Psychiatry90(2): 109–117.
31.
PrudicJOlfsonMMarcusSC, et al. (2004) Effectiveness of electroconvulsive therapy in community settings. Biological Psychiatry55(3): 301–312.
32.
RasmussenKGLineberryTWGalardyCW, et al. (2013) Serial infusions of low-dose ketamine for major depression. Journal of Psychopharmacology27(5): 444–450.
33.
SackeimHAHaskettRFMulsantBH, et al. (2001) Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy. JAMA285(10): 1299.
34.
SalloumNCFavaMHockRS, et al. (2020) Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. Journal of Affective Disorders260: 131–139.
ShiromaPRJohnsBKuskowskiM, et al. (2014) Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. Journal of Affective Disorders155: 123–129.
37.
ShiromaPRThurasPWelsJ, et al. (2020) A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Translational Psychiatry10(1): 206.
38.
SterneJHigginsJ (2024) The risk of bias in non-randomized studies – of interventions, version 2 (ROBINS-I V2) assessment tool.
39.
SterneJACSavovićJPageMJ, et al. (2019) RoB 2: A revised tool for assessing risk of bias in randomised trial. BMJ366: l4898.
40.
VeraartJKSmith-ApeldoornSYVan Der MeijA, et al. (2025) Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program. Journal of Psychopharmacology39(6): 559–570.
41.
WilkinsonSTBallardEDBlochMH, et al. (2017) Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychotherapy and Psychosomatics86(3): 162–167. https://doi.org/10.1159/000457960
ZanosPMoaddelRMorrisPJ, et al. (2018) Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacological Reviews70(3): 621–660.
45.
ZarateCAPayneJLQuirozJ, et al. (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. American Journal of Psychiatry161(1): 171–174.
46.
ZarateCASinghJBCarlsonPJ, et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry63(8): 856.
